Tempus AI (NASDAQ:TEM) Price Target Raised to $80.00

Tempus AI (NASDAQ:TEM) had its target price increased by equities researchers at BTIG Research from $70.00 to $80.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 30.61% from the stock’s current price.

Several other research firms have also commented on TEM. Wolfe Research started coverage on Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Freedom Capital raised Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Piper Sandler lowered their price target on Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a report on Tuesday, August 4th. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Stifel Nicolaus cut their price objective on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a report on Monday, August 3rd. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $65.69.

Tempus AI Stock Up 24.1%

TEM stock opened at $61.25 on Thursday. The stock has a market capitalization of $11.05 billion, a P/E ratio of -42.53 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI has a one year low of $40.77 and a one year high of $104.32. The company has a 50 day moving average price of $52.10 and a two-hundred day moving average price of $51.16.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the prior year, the company posted ($0.22) EPS. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. As a group, sell-side analysts expect that Tempus AI will post -1.38 EPS for the current year.

Insider Transactions at Tempus AI

In other news, Director Jennifer A. Doudna sold 2,673 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $147,015.00. Following the transaction, the director directly owned 25,942 shares in the company, valued at $1,426,810. This trade represents a 9.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the transaction, the chief executive officer directly owned 200,000 shares in the company, valued at $8,412,000. This represents a 55.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 684,424 shares of company stock worth $33,255,565 over the last ninety days. 24.26% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after acquiring an additional 817,014 shares in the last quarter. ARK Investment Management LLC lifted its holdings in shares of Tempus AI by 5.3% during the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after acquiring an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC acquired a new position in shares of Tempus AI during the 4th quarter valued at $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. boosted its position in Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after purchasing an additional 821,490 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.